Shari Rogal1,2,3, Ada Youk1,4, Hongwei Zhang1, Walid F Gellad1,5, Michael J Fine1,5, Chester B Good1,5,6, Maggie Chartier7, Andrea DiMartini2,8, Timothy Morgan9,10, Ramon Bataller3, Kevin L Kraemer1,5. 1. Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA. 2. Department of Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, PA. 3. Division of Gastroenterology, Hepatology, and Nutrition, School of Medicine, University of Pittsburgh, Pittsburgh, PA. 4. Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA. 5. Division of General Internal Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA. 6. Centers for Value Based Pharmacy Initiatives and High Value Health Care, UPMC Health Plan Insurance Division, Pittsburgh, PA. 7. HIV, Hepatitis, and Related Conditions Programs, Office of Specialty Care Services, Veterans Health Administration, Washington, DC. 8. Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA. 9. Gastroenterology Section, VA Long Beach Healthcare System, Long Beach, CA. 10. Division of Gastroenterology, Department of Medicine, University of California, Irvine, CA.
Abstract
BACKGROUND AND AIMS: Despite the significant medical and economic consequences of coexisting alcohol use disorder (AUD) in patients with cirrhosis, little is known about AUD treatment patterns and their impact on clinical outcomes in this population. We aimed to characterize the use of and outcomes associated with AUD treatment in patients with cirrhosis. APPROACH AND RESULTS: This retrospective cohort study included Veterans with cirrhosis who received Veterans Health Administration care and had an index diagnosis of AUD between 2011 and 2015. We assessed the baseline factors associated with AUD treatment (pharmacotherapy or behavioral therapy) and clinical outcomes for 180 days following the first AUD diagnosis code within the study time frame. Among 93,612 Veterans with cirrhosis, we identified 35,682 with AUD, after excluding 2,671 who had prior diagnoses of AUD and recent treatment. Over 180 days following the index diagnosis of AUD, 5,088 (14%) received AUD treatment, including 4,461 (12%) who received behavioral therapy alone, 159 (0.4%) who received pharmacotherapy alone, and 468 (1%) who received both behavioral therapy and pharmacotherapy. In adjusted analyses, behavioral and/or pharmacotherapy-based AUD treatment was associated with a significant reduction in incident hepatic decompensation (6.5% vs. 11.6%, adjusted odds ratio [AOR], 0.63; 95% confidence interval [CI], 0.52, 0.76), a nonsignificant decrease in short-term all-cause mortality (2.6% vs. 3.9%, AOR, 0.79; 95% CI, 0.57, 1.08), and a significant decrease in long-term all-cause mortality (51% vs. 58%, AOR, 0.87; 95% CI, 0.80, 0.96). CONCLUSIONS: Most Veterans with cirrhosis and coexisting AUD did not receive behavioral therapy or pharmacotherapy treatment for AUD over a 6-month follow-up. The reductions in hepatic decompensation and mortality suggest that future studies should focus on delivering evidence-based AUD treatments to patients with coexisting AUD and cirrhosis.
BACKGROUND AND AIMS: Despite the significant medical and economic consequences of coexisting alcohol use disorder (AUD) in patients with cirrhosis, little is known about AUD treatment patterns and their impact on clinical outcomes in this population. We aimed to characterize the use of and outcomes associated with AUD treatment in patients with cirrhosis. APPROACH AND RESULTS: This retrospective cohort study included Veterans with cirrhosis who received Veterans Health Administration care and had an index diagnosis of AUD between 2011 and 2015. We assessed the baseline factors associated with AUD treatment (pharmacotherapy or behavioral therapy) and clinical outcomes for 180 days following the first AUD diagnosis code within the study time frame. Among 93,612 Veterans with cirrhosis, we identified 35,682 with AUD, after excluding 2,671 who had prior diagnoses of AUD and recent treatment. Over 180 days following the index diagnosis of AUD, 5,088 (14%) received AUD treatment, including 4,461 (12%) who received behavioral therapy alone, 159 (0.4%) who received pharmacotherapy alone, and 468 (1%) who received both behavioral therapy and pharmacotherapy. In adjusted analyses, behavioral and/or pharmacotherapy-based AUD treatment was associated with a significant reduction in incident hepatic decompensation (6.5% vs. 11.6%, adjusted odds ratio [AOR], 0.63; 95% confidence interval [CI], 0.52, 0.76), a nonsignificant decrease in short-term all-cause mortality (2.6% vs. 3.9%, AOR, 0.79; 95% CI, 0.57, 1.08), and a significant decrease in long-term all-cause mortality (51% vs. 58%, AOR, 0.87; 95% CI, 0.80, 0.96). CONCLUSIONS: Most Veterans with cirrhosis and coexisting AUD did not receive behavioral therapy or pharmacotherapy treatment for AUD over a 6-month follow-up. The reductions in hepatic decompensation and mortality suggest that future studies should focus on delivering evidence-based AUD treatments to patients with coexisting AUD and cirrhosis.
Authors: Emily C Williams; Carol E Achtmeyer; Jessica P Young; Douglas Berger; Geoffrey Curran; Katharine A Bradley; Julie Richards; Michael B Siegel; Evette J Ludman; Gwen T Lapham; Mark Forehand; Alex H S Harris Journal: J Gen Intern Med Date: 2017-10-30 Impact factor: 5.128
Authors: Cynthia L Vuittonet; Michael Halse; Lorenzo Leggio; Samuel B Fricchione; Michael Brickley; Carolina L Haass-Koffler; Tonya Tavares; Robert M Swift; George A Kenna Journal: Am J Health Syst Pharm Date: 2014-08-01 Impact factor: 2.637
Authors: Victor I Reus; Laura J Fochtmann; Oscar Bukstein; A Evan Eyler; Donald M Hilty; Marcela Horvitz-Lennon; Jane Mahoney; Jagoda Pasic; Michael Weaver; Cheryl D Wills; Jack McIntyre; Jeremy Kidd; Joel Yager; Seung-Hee Hong Journal: Am J Psychiatry Date: 2018-01-01 Impact factor: 18.112
Authors: José Altamirano; Hugo López-Pelayo; Javier Michelena; Patricia D Jones; Lluisa Ortega; Pere Ginès; Juan Caballería; Antoni Gual; Ramón Bataller; Anna Lligoña Journal: Hepatology Date: 2017-12 Impact factor: 17.425
Authors: Ashwani K Singal; Andrea DiMartini; Lorenzo Leggio; Juan P Arab; Yong-Fang Kuo; Vijay H Shah Journal: Alcohol Alcohol Date: 2022-09-10 Impact factor: 3.913
Authors: Ashwani K Singal; Paul Kwo; Allison Kwong; Suthat Liangpunsakul; Alexandre Louvet; Pranoti Mandrekar; Craig McClain; Jessica Mellinger; Gyongyi Szabo; Norah Terrault; Mark Thursz; Gerald S Winder; W Ray Kim; Vijay H Shah Journal: Hepatology Date: 2021-11-27 Impact factor: 17.298